Summary
Global Markets Direct’s, ‘Promius Pharma, LLC - Product Pipeline Review - 2016’, provides an overview of the Promius Pharma, LLC’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Promius Pharma, LLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Promius Pharma, LLC
- The report provides overview of Promius Pharma, LLC including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Promius Pharma, LLC’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Promius Pharma, LLC’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Promius Pharma, LLC’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Promius Pharma, LLC
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Promius Pharma, LLC’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Promius Pharma, LLC Snapshot 6
Promius Pharma, LLC Overview 6
Key Information 6
Key Facts 6
Promius Pharma, LLC - Research and Development Overview 7
Key Therapeutic Areas 7
Promius Pharma, LLC - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Promius Pharma, LLC - Pipeline Products Glance 12
Promius Pharma, LLC - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
Promius Pharma, LLC - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Promius Pharma, LLC - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Promius Pharma, LLC - Drug Profiles 17
DFD-01 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
DFN-11 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
tetracycline MR 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
DFD-06 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
DFD-10 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
DFN-02 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ACT-01 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
celecoxib 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
DFN-10 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
DFN-15 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
DFN-14 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
DFN-19 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
DFD-04 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DFD-05 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DFD-08 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules 1 for Epilepsy 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules 1 for Parkinson's Disease 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules 2 for Epilepsy 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules 2 for Parkinson's Disease 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules 3 for Epilepsy 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules 3 for Parkinson's Disease 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules 4 for Epilepsy 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules 4 for Parkinson's Disease 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Promius Pharma, LLC - Pipeline Analysis 40
Promius Pharma, LLC - Pipeline Products by Target 40
Promius Pharma, LLC - Pipeline Products by Route of Administration 41
Promius Pharma, LLC - Pipeline Products by Molecule Type 42
Promius Pharma, LLC - Pipeline Products by Mechanism of Action 43
Promius Pharma, LLC - Recent Pipeline Updates 44
Promius Pharma, LLC - Dormant Projects 45
Promius Pharma, LLC - Locations And Subsidiaries 46
Head Office 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48
List of Tables
Promius Pharma, LLC, Key Information 6
Promius Pharma, LLC, Key Facts 6
Promius Pharma, LLC - Pipeline by Indication, 2016 8
Promius Pharma, LLC - Pipeline by Stage of Development, 2016 10
Promius Pharma, LLC - Monotherapy Products in Pipeline, 2016 11
Promius Pharma, LLC - Pre-Registration, 2016 12
Promius Pharma, LLC - Phase III, 2016 13
Promius Pharma, LLC - Phase II, 2016 14
Promius Pharma, LLC - Phase I, 2016 15
Promius Pharma, LLC - Preclinical, 2016 16
Promius Pharma, LLC - Pipeline by Target, 2016 40
Promius Pharma, LLC - Pipeline by Route of Administration, 2016 41
Promius Pharma, LLC - Pipeline by Molecule Type, 2016 42
Promius Pharma, LLC - Pipeline Products by Mechanism of Action, 2016 43
Promius Pharma, LLC - Recent Pipeline Updates, 2016 44
Promius Pharma, LLC - Dormant Developmental Projects,2016 45
List of Figures
Promius Pharma, LLC - Pipeline by Indication, 2016 8
Promius Pharma, LLC - Pipeline by Stage of Development, 2016 10
Promius Pharma, LLC - Monotherapy Products in Pipeline, 2016 11
Promius Pharma, LLC - Pipeline by Target, 2016 40
Promius Pharma, LLC - Pipeline by Route of Administration, 2016 41
Promius Pharma, LLC - Pipeline by Molecule Type, 2016 42
Promius Pharma, LLC - Pipeline Products by Mechanism of Action, 2016 43
